Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Optic atrophy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Optic atrophy. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-001034-42 Sponsor Protocol Number: SNT-II-003-OFU Start Date*: 2011-08-25
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: A single visit, observational, follow-up study of Patients with Leber’s Hereditary Optic Neuropathy following participation in SNT-II-003 trial
    Medical condition: Leber’s Hereditary Optic Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001405-90 Sponsor Protocol Number: GS-LHON/CLIN/01 Start Date*: 2013-12-26
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001493-28 Sponsor Protocol Number: OPA1 Start Date*: 2020-09-24
    Sponsor Name:Medizinische Universität Graz, Univ.-Augenklinik
    Full Title: Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation
    Medical condition: Autosomal dominant optic atrophy (ADOA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019895 Hereditary optic atrophy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002187-40 Sponsor Protocol Number: GS-LHON-CLIN-05 Start Date*: 2018-03-15
    Sponsor Name:GENSIGHT BIOLOGICS
    Full Title: Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected with G11778A ND4 Leber Hereditary Optic Neuropathy for U...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002153-11 Sponsor Protocol Number: GS-LHON-CLIN-06 Start Date*: 2018-02-12
    Sponsor Name:GENSIGHT BIOLOGICS
    Full Title: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003475-11 Sponsor Protocol Number: UCL/11/0083 Start Date*: 2011-11-15
    Sponsor Name:University College London (UCL)
    Full Title: A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis
    Medical condition: Acute demyelinating optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005113-39 Sponsor Protocol Number: SSP-2 Start Date*: 2013-04-08
    Sponsor Name:Universitätsklinik für Neurologie, Medizinische Universität Wien
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis
    Medical condition: Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004405-16 Sponsor Protocol Number: SNT-IV-005 Start Date*: 2016-03-16
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: External Natural History Controlled, open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone® in Leber’s Hereditary Optic Neuropathy (LHON)
    Medical condition: Leber’s Hereditary Optic Neuropathy / LHON is a maternally inherited loss of vision due to atrophy of the optic nerve. It typically presents in young adults, mostly men, as painless acute or subacu...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed) PT (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004594-43 Sponsor Protocol Number: ISTEM02 Start Date*: 2021-05-27
    Sponsor Name:CECS/I-Stem
    Full Title: AUDIOWOLF: A phase II, open-label, efficacy study of daily administration of sodium valproate in patients clinically affected by Wolfram syndrome due to monogenic mutation
    Medical condition: Wolfram syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001265-11 Sponsor Protocol Number: GS-LHON-CLIN-03A Start Date*: 2016-01-21
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for 6 Months or Less by...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005592-14 Sponsor Protocol Number: 26 Start Date*: 2006-07-27
    Sponsor Name:IFSgGmbH, Institute for clinical research
    Full Title: Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PRO...
    Medical condition: Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004807-10 Sponsor Protocol Number: inims-004 Start Date*: 2013-07-17
    Sponsor Name:University Medical Center Hamburg Eppendorf
    Full Title: Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuri...
    Medical condition: MS patients who suffer from severe Optic Neuritis without satisfying improvement after treatment with steroids (3-5 days with 1 g daily at least 7 days prior to randomization) and with persisting v...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10070425 Multiple sclerosis exacerbation LLT
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002531-15 Sponsor Protocol Number: 09/0959 Start Date*: 2016-11-14
    Sponsor Name:UCL Comprehensive Clinical Trials Unit
    Full Title: A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis
    Medical condition: Glaucoma, Age-related Macular Degeneration, and Optic Neuritis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10047560 Visual field perimetric tests LLT
    19.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    19.0 100000004867 10021948 Infiltration intravenous injection LLT
    19.0 10022891 - Investigations 10057208 Optical coherence tomography PT
    19.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    19.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    19.0 10022891 - Investigations 10047566 Visual field tests PT
    19.0 10015919 - Eye disorders 10009034 Chronic open angle glaucoma LLT
    19.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    19.0 10015919 - Eye disorders 10006027 Borderline glaucoma PT
    19.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    19.0 10015919 - Eye disorders 10006028 Borderline glaucoma (glaucoma suspect) LLT
    19.0 10029205 - Nervous system disorders 10004571 Bilateral optic neuritis LLT
    19.0 10029205 - Nervous system disorders 10012121 Defect visual field (NOS) LLT
    19.0 100000004865 10020422 HRT LLT
    19.0 10015919 - Eye disorders 10018304 Glaucoma PT
    19.0 100000004865 10048541 Intravenous catheter management LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005213-22 Sponsor Protocol Number: SUPREMES-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: SUPREMES - Sunphenon in progressive forms of multiple sclerosis
    Medical condition: primary and secondary progressive forms of multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001487-37 Sponsor Protocol Number: 190342-032D Start Date*: 2008-11-05
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Br...
    Medical condition: Geographic Atrophy from Age-related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001266-26 Sponsor Protocol Number: GS-LHON-CLIN-03B Start Date*: 2016-01-21
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 months a...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003320-36 Sponsor Protocol Number: 190342-038 Start Date*: 2015-03-02
    Sponsor Name:Allergan Limited
    Full Title: Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)
    Medical condition: Geographic Atrophy Secondary to Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001215-37 Sponsor Protocol Number: RG_16_211 Start Date*: 2018-03-19
    Sponsor Name:University of Birmingham
    Full Title: A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valporate in paediatric and adult patients with Wolfram Syndrome
    Medical condition: Wolfram syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003853-70 Sponsor Protocol Number: PNRR-MR1-2022-12375914 Start Date*: 2023-05-02
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose­ dependent insulinotropic polypeptide and glucagon-like peptide-I receptor agonist) monotherapy in patients wi...
    Medical condition: Wolfram syndrome type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004157-66 Sponsor Protocol Number: QRK202 Start Date*: 2012-05-29
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety...
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:15:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA